Elsevier

Vaccine

Volume 27, Issue 50, 23 November 2009, Pages 7131-7132
Vaccine

Short report
Molecular epidemiology of Japanese encephalitis in East Asia

https://doi.org/10.1016/j.vaccine.2009.09.051Get rights and content

Abstract

Japanese encephalitis virus is genetically divided into five genotypes. Until the early 1990s, only genotype-3 JE virus was identified in Japan, then, the genotype shifted to type-1 countrywide.

Based on our molecular epidemiological study of JEV in Vietnam, China, and Japan, 8 subgroups of genotype 1 JEVs are circulating in East Asia and, at least, 4 of these subgroups are chronologically related and frequently introduced to Japan through China.

Possibly, this subgroup distribution is due to bird migration and/or infected mosquitoes which carry viruses for long distances. While in Japan, a small population of genotype 1 is circulating locally.

References (9)

There are more references available in the full text version of this article.

Cited by (24)

  • Lentivirus-mediated RNA interference against Japanese encephalitis virus infection in vitro and in vivo

    2014, Antiviral Research
    Citation Excerpt :

    Mainly based on the E gene, JEV is divided into five genotypes (I–V). Genotypes I and III are epidemic in East and Southeast Asia (Morita, 2009; Gao et al., 2013). RNA interference (RNAi), a post-transcriptional mechanism widely present in eukaryotes, is an evolutionarily conserved process of specific gene silencing (Bosher and Labouesse, 2000; Hannon, 2002).

  • Reduced neutralizing antibody titer against genotype I virus in swine immunized with a live-attenuated genotype III Japanese encephalitis virus vaccine

    2013, Veterinary Microbiology
    Citation Excerpt :

    Serum from at222-vaccinated piglets exhibits greater GIII than GI strain-specific neutralization. There are five amino acid discrepancies between GIII and GI JEV in the E protein, including residues 123, 129, and 222 located in domain II; and 327 and 366 in domain III (Chen, 2012; Morita, 2009). The E domain III is the most critical domain for eliciting neutralizing antibody (Luca et al., 2012; Tang et al., 2010).

View all citing articles on Scopus
View full text